We evaluated the effects of transcranial random noise stimulation (tRNS) on fatigue in 17 subjects with relapsing-remitting multiple sclerosis with low physical disability. Two different patient groups underwent real or sham stimulation for 10 days, targeting the primary motor cortex of the dominant side or contralateral to the most compromised limb. In the 'real group', beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales 'change in health' (p = 0.006) and 'role limitations due to physical problems' (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue (p = 0.005).
Introduction
Fatigue is one of the most common, early, and disabling symptoms in multiple sclerosis (MS). Its prevalence ranges from 80-85%, in the first stages of the disease, to 90-95% with disability progression (Nagaraj et al. 2013) . Because of its subjectivity and frequent overlapping with other morbid conditions, its management turns out to be quite difficult and frequently requires multiple approaches (Chalah et al. 2015) .
Among electrical forms of non-invasive brain stimulation (NIBS) techniques, only transcranial direct current stimulation (tDCS) has been applied so far to the brain cortex aiming to improve MS fatigue with encouraging results Chalah et al. 2017a, b; Charvet et al. 2018; Ferrucci et al. 2014; Lefaucheur et al. 2017; Saiote et al. 2014) . A promising new technique of NIBS is the transcranial random noise stimulation (tRNS). During tRNS, an alternating current is applied, with randomized frequencies ranging from 0.1 to 640 Hz. tRNS modulates cortical excitability (Nagaraj et al. 2013 ) also generating after-effects due to changes in synaptic plasticity and activity (Antal and Herrmann 2016) . These effects seem to depend on a mechanism known as "stochastic resonance", a phenomenon in which the presence of noise in a nonlinear system leads to a better quality of output signal compared with its absence (Fertonani et al. 2011; Terney et al. 2008) . Interestingly, tRNS has proven to induce stronger facilitatory effects on the motor cortex excitability with respect to anodal tDCS (Inukai et al. 2016) . Palm et al. (2016) , in a study designed to evaluate the effect of tRNS on pain and attention in MS, have not shown significant beneficial effects on fatigue when applying the active electrode on the left side of the dorso-lateral prefrontal cortex (DLPFC).
In the current work, we aim to evaluate the effect on MS fatigue when tRNS is applied on the primary motor cortex (M1) of the dominant side or contralateral to the most compromised limb. As a secondary outcome, we evaluate the Giuseppe Salemi and Giulia Vazzoler contributed equally to all the phases of the study.
Patients and methods
We performed a pilot randomized sham-controlled singleblind study.
We included subjects affected by relapsing-remitting MS (Polman et al. 2011 ) and referred fatigue with low physical disability. For the purposes of this study, to limit the confounding effect of disability on fatigue, we defined a status of low physical disability as a condition corresponding to a score at Modified Fatigue Impact Scale (MFIS) > 20 (Kos et al. 2003 ) and at Expanded Disability Status Scale (EDSS) ≤ 4.5 (Kurtzke 1983) . We selected the coupling of these two threshold scores because in this way we thought to select a population with limited fatigue and low disability. We excluded subjects unable to sign written consent, pregnant and breastfeeding women, subjects who had taken steroids in the previous 30 days, or subjects with variation of pharmacological fatigue therapy in the previous 90 days from the beginning of the experimental session. Finally, we excluded subjects with a score ≥ 14 at the Beck Depression Inventory-II.
Through the use of a transcranial electric stimulator (Brainstim stimulator, EMS, Bologna, Italy) each patient, randomly included in the real group, received a tRNS consisting of an alternating current at 1.5 mA intensity with no offset, applied at random frequencies ranging from 100 to 640 Hz (highfrequency tRNS), daily over M1 for 15 min over two consecutive weeks (from Monday to Friday). Patients included in the sham group received tRNS stimulation for 30 s, after which the stimulator automatically turned off for the remaining time to reach 15 min and 30" before the end automatically it turned on to deliver current; this for the same number of days as in the real group. Subjects were blind to the type of stimulation. We used sponge electrodes of 50 × 50 mm that were soaked in saline solution. A large strip electrode was positioned, to cover the whole motor cortex, on M1 of the left side, except when evident clinical asymmetries were observed, and the other in the frontal opposite cortex. To localize M1 and the opposite site, we used a 10-20 EEG system and the electrodes were placed at C3 + FP2 and C4 + FP1.
To evaluate fatigue, we used the MFIS, an instrument which rates fatigue's impact on three different domains (physical, cognitive and psychosocial); we administered it at baseline (T0), after 1 week (T1), after the last stimulation (T2), and 30 days after the last stimulation (T3). To evaluate the impact of stimulation on cognitive functions, we applied the Brief International Cognitive Assessment for MS (BICAMS) at T0 and T2; while for manual dexterity and bimanual coordination, the Purdue Pegboard Instrument (PPI) at T0 and T2 was performed. To assess fatigability, we used the Timed 25 Foot Walking Test (T25FWT) at T0, T1, and T2, while the Multiple Sclerosis Quality of Life-54 (MSQoL-54) questionnaire was performed at T0 and T3 to assess quality of life. MFIS and MSQol-54 at T3 were self-administered and sent to us through internet. Finally, at the end of the stimulation period (T2), we asked the subjects if they perceived an improvement in fatigue.
The statistical analysis was done using SPSS software (SPSS, Inc., Chicago, IL, USA). To compare the sociodemographic and clinical characteristics between both groups (real versus sham), we performed Student's t test for continuous data or the χ 2 test for categorical data. Tests administered at different times (MFIS, BICAMS, T25WT, PPI, and MSQoL-54) were submitted to two-way ANOVA. Significant differences at two-tailed α level were set at p ≤ 0.05 and Bonferroni-Sidak multiple comparison test was employed as a post hoc test. The evaluation of the perceived improvement of fatigue at T2 was based on a yes/no response and the group differences were assessed by the χ 2 test.
Results
We enrolled 17 subjects of which 9 were given a real stimulation, and 8 a sham stimulation. After the stimulation, one subject from the real group reported mild headache and two, one from the real group and the other from the sham group, mild burning sensation in the region under the electrodes. Table 1 shows the demographic and clinical features of the two groups at baseline; we did not observe significant differences for all the variables analyzed, indicating that the two groups were comparable. Table 2 shows the results of the comparisons for the selected item of evaluations. We did not find differences at baseline between the two groups. Main findings were represented by (1) a significant score decrease in the "real" group between T0 and T2 at the MFIS global scale (twoway ANOVA p = 0.04; Sidak multiple comparison test: real p = 0.04) and at the MFIS physical subscale (two-way ANOVA p = 0.009; Sidak multiple comparison test: real p = 0.0008); (2) a significant score increase in the "real" group for the two subscales of MSQoL-54 "change in health" (two-way ANOVA p = 0.006; Sidak multiple comparison test: real p = 0.0004) and "role limitations due to physical problems" (two-way ANOVA p = 0.001; Sidak multiple comparison test: real p = 0.001). Finally, while all subjects treated with real tRNS reported a subjective improvement in fatigue, only one person that underwent sham stimulation referred a clinical improvement (p = 0.005). (Korzhova et al. 2018) , pain (Curatolo et al. 2017 ) and neglect (Bornheim et al. 2018 ).
The temporal effects observed with MFIS global and physical subscales are intriguing. We observed a difference in favor of the real group after five sessions (T1) that became statistically significant after ten sessions (T2), but did not persist at day 30 following the last stimulation. This suggests the need to repeat the stimulation to 'cumulate' the beneficial effects as suggested in various papers on tDCS Chalah et al. 2017a, b; Charvet et al. 2018; Ferrucci et al. 2014; Lefaucheur et al. 2017; Saiote et al. 2014) . Another important finding is the absence of effect on the cognitive/psychosocial domains which might suggest that tRNS over M1 may only target the physical part of fatigue and other cortical areas might be tested to induce cognitive/psychosocial changes. However, our study has some limitations: the low number of subjects treated and various critical issues related to fatigue (i.e., the extreme variability across time and the influence of external factors such as stress, drowsiness, excessive daytime sleepiness, and mood). Moreover, the low disability level of our sample could explain why not significant changes were detected by the T25FWT. However, the homogeneity of clinical and demographic features of the two groups is a strength of the study.
Future plans include an extension of the study to a larger sample; if the therapeutic effect will be confirmed, efforts could be made to widespread this safe treatment strategy to a larger population.
